Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Zohreh, J; Alexander, S; Ines, A; Florian, K; Birgit, L; Christin, D; Rudolf, B; Alexander, D; Beate, R; Nadine, K.
Influence of silibinin and β-β-dimethylacrylshikonin on chordoma cells.
Phytomedicine. 2018; 49:32-40
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Anders Ines
Deutsch Alexander
Kleinegger Florian
Lohberger Birgit
Rinner Beate
Stallinger Alexander
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
Chordoma, slow growing bone tumours originating from remnants of the notochord, leave affected patients with a median survival of six years. The high recurrence rate of chordoma, together with limited treatment options and bad overall prognosis, make the development of new treatment options urgently necessary. In this study, the potential of two natural products, silibinin and β-β-dimethylacrylshikonin (DMAS), was tested on clival (MUG-CC1 and UM-Chor1) as well as sacral (MUG-Chor1 and U-CH2) chordoma cell lines. The treatment was administered both as single- and combined therapy. For investigation of cell viability, the Cell Titer 96 Aqueous Non-Radioactive Cell Proliferation Assay Kit was used. Apoptosis induction was studied by flow cytometry, (Annexin V/SYTOX Green, caspase-3) and RT-qPCR. Pathway analyses were performed by western blot. Both drugs were found to reduce cell viability alone as well as in combination in a dose dependent manner, with DMAS being more efficient than silibinin. The mode of cell death was mainly apoptosis in DMAS treated samples, while the combination therapy led to apoptosis as well as late-apoptosis/necrosis. Silibinin therapy alone, although reducing cell viability, did not lead to significant apoptotic effects in the performed assays. Focussing on the molecular mechanism of DMAS induced apoptosis, it was found that major genes of the mitochondrial apoptosis pathway, like NOXA and PUMA were overexpressed. Additionally, western blot experiments showed a decrease of ERK/pERK, STAT3/pSTAT3 (Tyr705) and AKT/pAKT expression/activation levels under DMAS treatment. DMAS is a promising new candidate for chordoma therapy, while silibinin or a combination of both is less favourable. Copyright © 2018. Published by Elsevier GmbH.

Find related publications in this database (Keywords)
Chordoma
beta-beta-dimethylacrylshikonin
Silibinin
Apoptosis
© Meduni Graz Impressum